GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PYC Therapeutics Ltd (ASX:PYC) » Definitions » EV-to-Revenue

PYC Therapeutics (ASX:PYC) EV-to-Revenue : (As of Jun. 12, 2024)


View and export this data going back to 2005. Start your Free Trial

What is PYC Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, PYC Therapeutics's enterprise value is A$465.07 Mil. PYC Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil. Therefore, PYC Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for PYC Therapeutics's EV-to-Revenue or its related term are showing as below:

During the past 13 years, the highest EV-to-Revenue of PYC Therapeutics was 133.91. The lowest was 1.39. And the median was 28.73.

ASX:PYC's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.895
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-12), PYC Therapeutics's stock price is A$0.105. PYC Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00. Therefore, PYC Therapeutics's PS Ratio for today is .


PYC Therapeutics EV-to-Revenue Historical Data

The historical data trend for PYC Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PYC Therapeutics EV-to-Revenue Chart

PYC Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PYC Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PYC Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, PYC Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PYC Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PYC Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where PYC Therapeutics's EV-to-Revenue falls into.



PYC Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

PYC Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=465.069/0
=

PYC Therapeutics's current Enterprise Value is A$465.07 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PYC Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PYC Therapeutics  (ASX:PYC) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

PYC Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.105/0
=

PYC Therapeutics's share price for today is A$0.105.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PYC Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of PYC Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


PYC Therapeutics (ASX:PYC) Business Description

Traded in Other Exchanges
N/A
Address
6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.

PYC Therapeutics (ASX:PYC) Headlines

No Headlines